Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels

References

• Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, Musumeci G. 2022. “No-reflow” phenomenon: a contemporary review. J Clin Med. 11:2233.
   PubMed Web of Science ®Google Scholar
• Bai S, Wang X, Wu H, Chen T, Li X, Zhang L, Li X, Er L, Du R. 2021. Cardioprotective effect of anisodamine against ischemia/reperfusion injury through the mitochondrial ATP-sensitive potassium channel. Eur J Pharmacol. 901:174095.
   PubMed Web of Science ®Google Scholar
• Bullen JW, Tchernyshyov I, Holewinski RJ, DeVine L, Wu F, Venkatraman V, Kass DL, Cole RN, Van Eyk J, Semenza GL. 2016. Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci Signal. 9:ra56.
   PubMed Web of Science ®Google Scholar
• Cai X, Du J, Li L, Zhang P, Zhou H, Tan X, Li Y, Yu C. 2018. Clinical metabolomics analysis of therapeutic mechanism of Tongmai Yangxin Pill on stable angina. J Chromatogr B Analyt Technol Biomed Life Sci. 1100-1101:106–112.
   PubMed Web of Science ®Google Scholar
• Chen R, Chen T, Wang T, Dai X, Meng K, Zhang S, Jiang D, Wang Y, Zhou K, Geng T, et al. 2020. Tongmai Yangxin pill reduces myocardial no-reflow by regulating apoptosis and activating PI3K/Akt/eNOS pathway. J Ethnopharmacol. 261:113069.
   PubMed Web of Science ®Google Scholar
• Chen R, Chen T, Wang T, Dai X, Zhang S, Jiang D, Meng K, Wang Y, Geng T, Xu J, et al. 2021. Tongmai Yangxin pill reduces myocardial No-reflow via endothelium-dependent NO-cGMP signaling by activation of the cAMP/PKA pathway. J Ethnopharmacol. 267:113462.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lin T, Liao X, Li Z, Lin R, Qi X, Chen G, Sun L, Lin L. 2021. Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against cholangiocarcinoma. Chin Med. 16:13.
   PubMed Web of Science ®Google Scholar
• Cohen MV, Yang XM, Downey JM. 2006. Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res. 70:231–239.
   PubMed Web of Science ®Google Scholar
• Dang Y, Ma X, Li Y, Hao Q, Xie Y, Zhang Q, Zhang F, Qi X. 2018. Inhibition of SETD7 protects cardiomyocytes against hypoxia/reoxygenation-induced injury through regulating Keap1/Nrf2 signaling. Biomed Pharmacother. 106:842–849.
   PubMed Web of Science ®Google Scholar
• Datta Chaudhuri R, Banik A, Mandal B, Sarkar S. 2021. Cardiac-specific overexpression of HIF-1α during acute myocardial infarction ameliorates cardiomyocyte apoptosis via differential regulation of hypoxia-inducible pro-apoptotic and anti-oxidative genes. Biochem Biophys Res Commun. 537:100–108.
   PubMed Web of Science ®Google Scholar
• Dong LY, Chen F, Xu M, Yao LP, Zhang YJ, Zhuang Y. 2018. Quercetin attenuates myocardial ischemia-reperfusion injury via downregulation of the HMGB1-TLR4-NF-κB signaling pathway. Am J Transl Res. 10:1273–1283.
   PubMed Web of Science ®Google Scholar
• Fan Y, Liu J, Miao J, Zhang X, Yan Y, Bai L, Chang J, Wang Y, Wang L, Bian Y, et al. 2021. Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-κB signaling pathway. J Ethnopharmacol. 276:114106.
   PubMed Web of Science ®Google Scholar
• Fan Y, Man S, Li H, Liu Y, Liu Z, Gao W. 2016. Analysis of bioactive components and pharmacokinetic study of herb-herb interactions in the traditional Chinese patent medicine Tongmai Yangxin Pill. J Pharm Biomed Anal. 120:364–373.
   PubMed Web of Science ®Google Scholar
• Hansen FB, Esteves GV, Mogensen S, Prat-Duran J, Secher N, Løfgren B, Granfeldt A, Simonsen U. 2021. Increased cerebral endothelium-dependent vasodilation in rats in the postcardiac arrest period. J Appl Physiol. 131:1311–1327.
   PubMed Web of Science ®Google Scholar
• Hernández-Reséndiz S, Palma-Flores C, De Los Santos S, Román-Anguiano NG, Flores M, Peña A, Flores PL, Fernández-G JM, Coral-Vázquez RM, Zazueta C. 2015. Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound prolame is associated with PI3K/Akt/eNOS signaling cascade. Basic Res Cardiol. 110:1.
   PubMed Web of Science ®Google Scholar
• Hou F, Yu Z, Cheng Y, Liu Y, Liang S, Zhang F. 2022. Deciphering the pharmacological mechanisms of Scutellaria baicalensis Georgi on oral leukoplakia by combining network pharmacology, molecular docking and experimental evaluations. Phytomedicine. 103:154195.
   PubMed Web of Science ®Google Scholar
• Hu P, Sun N, Khan A, Zhang X, Sun P, Sun Y, Guo J, Zheng X, Yin W, Fan K, et al. 2021. Network pharmacology-based study on the mechanism of scutellarin against zearalenone-induced ovarian granulosa cell injury. Ecotoxicol Environ Saf. 227:112865.
   PubMed Web of Science ®Google Scholar
• Khan KA, Qamar N, Saghir T, Sial JA, Kumar D, Kumar R, Qayyum D, Yasin U, Jalbani J, Karim M. 2022. Comparison of intracoronary epinephrine and adenosine for no-reflow in normotensive patients with acute coronary syndrome (COAR Trial). Circ Cardiovasc Interv. 15:e011408.
   PubMed Web of Science ®Google Scholar
• Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S, Aittokallio T. 2015. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 32:1249–1266.
   PubMed Web of Science ®Google Scholar
• Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. 2005. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 46(11):2116–2124.
   PubMed Web of Science ®Google Scholar
• Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, Kerendi F, Guyton RA, Vinten-Johansen J. 2004. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 62:74–85.
   PubMed Web of Science ®Google Scholar
• Li Q, Guo Z, Wu C, Tu Y, Wu Y, Xie E, Yu C, Sun W, Li X, Zheng J, et al. 2022. Ischemia preconditioning alleviates ischemia/reperfusion injury-induced coronary no-reflow and contraction of microvascular pericytes in rats. Microvasc Res. 142:104349.
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Liang X, Yang L, Su M, Lai KP. 2021. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets. Brief Bioinform. 22:1279–1290.
   PubMed Web of Science ®Google Scholar
• Li S, Chen J, Liu M, Chen Y, Wu Y, Li Q, Ma T, Gao J, Xia Y, Fan M, et al. 2021. Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia-reperfusion injury. Basic Res Cardiol. 116:65.
   PubMed Web of Science ®Google Scholar
• Li S, Chen YT, Ding QY, Dai JY, Duan XC, Hu YJ, Lai XX, Liu QF, Niu M, Xiang RW, et al. 2021. Network pharmacology evaluation method guidance‐draft. World J Tradit Chin Med. 7(1):146–154.
   Google Scholar
• Lv K, Kong L, Yang M, Zhang L, Chu S, Zhang L, Yu J, Zhong G, Shi Y, Wang X, et al. 2022. An ApoA-I mimic peptide of 4F promotes SDF-1α expression in endothelial cells through PI3K/Akt/ERK/HIF-1α signaling pathway. Front Pharmacol. 12:760908.
   PubMed Web of Science ®Google Scholar
• Nadtochiy SM, Redman E, Rahman I, Brookes PS. 2011. Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res. 89(3):643–649.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G. 2019. Myeloperoxidase – A bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta. 493:36–51.
   PubMed Web of Science ®Google Scholar
• Niccoli G, Burzotta F, Galiuto L, Crea F. 2009. Myocardial no-reflow in humans. J Am Coll Cardiol. 54:281–292.
   PubMed Web of Science ®Google Scholar
• Quan X, Liu X, Qin X, Wang Y, Sun T, Li Z, Zhu L, Chen J, Zhou Y, Singh S, et al. 2021. The role of LR-TIMAP/PP1c complex in the occurrence and development of no-reflow. EBioMedicine. 65:103251.
   PubMed Web of Science ®Google Scholar
• Rajendran S, Sundaresan L, Venkatachalam G, Rajendran K, Behera J, Chatterjee S. 2022. Temporal dynamics of nitric oxide wave in early vasculogenesis. Vasc Med. 27(1):3–12.
   PubMed Web of Science ®Google Scholar
• Su D, Liao L, Zeng Q, Liao Z, Liu Y, Jin C, Zhu G, Chen C, Yang M, Ai Z, et al. 2022. Study on the new anti-atherosclerosis activity of different Herba patriniae through down-regulating lysophosphatidylcholine of the glycerophospholipid metabolism pathway. Phytomedicine. 94:153833.
   PubMed Web of Science ®Google Scholar
• Sumida A, Horiba M, Ishiguro H, Takenaka H, Ueda N, Ooboshi H, Opthof T, Kadomatsu K, Kodama I. 2010. Midkine gene transfer after myocardial infarction in rats prevents remodelling and ameliorates cardiac dysfunction. Cardiovasc Res. 86(1):113–121.
   PubMed Web of Science ®Google Scholar
• Tang J, Lu L, Liu Y, Ma J, Yang L, Li L, Guo H, Yu S, Ren J, Bai H, et al. 2019. Quercetin improves ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro and in vivo study via SIRT1/PGC-1α signaling. J Cell Biochem. 120:9747–9757.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang X, Li D, Hao W, Meng F, Wang B, Han J, Zheng Q. 2017. Kaempferide protects against myocardial ischemia/reperfusion injury through activation of the PI3K/Akt/GSK-3β pathway. Mediators Inflamm. 20172017::5278218.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Wang J, Li B, Yu R, Hu Y, Li X, Peng G, Zhang M, Zhu M. 2020. Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial. Trials. 21(1):287.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Xiao Y. 2011. The effect of Tongmai Yangxin Pill on the inflammatory factors and oxidative stress induced by hypoxia-induced myocardial cells. J Trad Chin Med. 52:326–328.
   Google Scholar
• Wang Y, Zhang ZZ, Wu Y, Ke JJ, He XH, Wang YL. 2013. Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway. Braz J Med Biol Res. 46:861–867.
   PubMed Web of Science ®Google Scholar
• Wei B, Lin Q, Ji YG, Zhao YC, Ding LN, Zhou WJ, Zhang LH, Gao CY, Zhao W. 2018. Luteolin ameliorates rat myocardial ischaemia-reperfusion injury through activation of peroxiredoxin II. Br J Pharmacol. 175:3315–3332.
   PubMed Web of Science ®Google Scholar
• Wei M, Li H, Li Q, Qiao Y, Ma Q, Xie R, Wang R, Liu Y, Wei C, Li B, et al. 2020. Based on network pharmacology to explore the molecular targets and mechanisms of Gegen Qinlian decoction for the treatment of ulcerative colitis. Biomed Res Int. 2020:5217405.
   PubMed Web of Science ®Google Scholar
• Xenogiannis I, Zenati M, Bhatt DL, Rao SV, Rodés-Cabau J, Goldman S, Shunk KA, Mavromatis K, Banerjee S, Alaswad K, et al. 2021. Saphenous vein graft failure: from pathophysiology to prevention and treatment strategies. Circulation. 144:728–745.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhang D, Zhou P, Li B, Huang SY. 2017. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 45(W1):W365–W373.
   PubMed Web of Science ®Google Scholar
• Yu D, Li M, Tian Y, Liu J, Shang J. 2015. Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury. Life Sci. 122:15–25.
   PubMed Web of Science ®Google Scholar
• Yu P, Li Y, Fu W, Li X, Liu Y, Wang Y, Yu X, Xu H, Sui D. 2021. Panax quinquefolius L. saponins protect myocardial ischemia reperfusion no-reflow through inhibiting the activation of NLRP3 inflammasome via TLR4/MyD88/NF-κB signaling pathway. Front Pharmacol. 11:607813.
   PubMed Web of Science ®Google Scholar
• Yu X, Li F, Klussmann E, Stallone JN, Han G. 2014. G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. Am J Physiol Endocrinol Metab. 307(4):E398–407.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hu M, Ma S. 2021. Association of soluble suppression of tumorigenicity with no-reflow phenomenon and long-term prognosis in patients with non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention. J Atheroscler Thromb. 28:1289–1297.
   PubMed Web of Science ®Google Scholar
• Zhang X, Du Q, Yang Y, Wang J, Dou S, Liu C, Duan J. 2017. The protective effect of luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3 inflammasome pathway. Biomed Pharmacother. 91:1042–1052.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhou Z, Zhu C, Fu Z, Yu D. 2020. Luteolin alleviates myocardial ischemia reperfusion injury in rats via Siti1/NLRP3/NF-κB pathway. Int Immunopharmacol. 85:106680.
   PubMed Web of Science ®Google Scholar
• Zhou M, Ren H, Han J, Wang W, Zheng Q, Wang D. 2015. Protective effects of kaempferol against myocardial ischemia/reperfusion injury in isolated rat heart via antioxidant activity and inhibition of glycogen synthase kinase-3β. Oxid Med Cell Longev. 2015:481405.
   PubMed Web of Science ®Google Scholar